Danish healthcare company Novo Nordisk has formalized a collaboration with Pune’s Emcure Pharmaceuticals on the former’s Wegovy, the injectable version of weightloss and diabetes drug semaglutide.

The announcement comes just weeks after fellow multinational who has similar products in the same segment, US company Eli Lilly announced its agreement with Cipla to sell tirzepatide in India, under a separate name, but at the same price as Mounjaro is sold in India.

Cipla will sell it under the brandname Yurpeak, they had said, adding that it too would be available in a pen-like device, in six different strengths. Lilly brought Mounjaro to India in March 2025, and announced its pen-like devices in June. The product grossed ₹100 crore in October, taking pole position in the Indian pharmaceutica

See Full Page